Skip to main content

Select Drug Profiles

Practice Management

The Incidence Rate and Economic Burden of Community-Acquired Pneumonia in a Working-Age Population

Jonah Broulette, ASA, MAAA, Holly Yu, MSPH, Kosuke Iwasaki, FIAJ, MAAA, Reiko Sato, PhD, Bruce S. Pyenson, FSA, MAAA

Stakeholder Perspective

CAP Is a Burden for All Ages—Prevention Strategies Are Key

by F. Randy Vogenberg, PhD, FASHP

Practice Management

Technological Changes Can Transform Medicine by 2020: A Conversation with the Futurist Jim Carroll

Rosemary Frei, MSc

Diagnosis and Management of Myelofibrosis: Practical Strategies for the Healthcare Team Proceedings from a Multidisciplinary Roundtable

Jason R. Gotlib, MD, MS

Intensive Treatment Early in Type 1 Diabetes Produces Substantial Long-Term Benefits

New Data Show Ranolazine Most Effective Antianginal Agent for Patients with Type 2 Diabetes and HbA1c >7%

Albiglutide, a GLP-1 Receptor Agonist, Effective in Various Treatment Scenarios in Patients with Type 2 Diabetes

Financial Incentives Can Promote Maintenance of Weight Loss, a Major Factor in Diabetes

Costs of Diabetes-Related Complications Reduced with Canagliflozin Monotherapy

Resource Utilization and Costs: Comparing Saxagliptin and Sitagliptin

Substantial Costs for Diabetes Are Consumed by the Diabetic Foot and Arthritis

Page 165 of 244
Results 1641 - 1650 of 2438